NVUS insider filings
Eledon Pharmaceuticals, Inc. — 8 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2020-12-28. Screen NVUS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for NVUS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Eledon Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2020-12-28 | 4 | BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC/IL LAMPERT MARK N | Conversion (C): 15,166 · Conversion (C): 654,215 · Conversion (C): 11,278 · Conversion (C): 509,410 · Conversion (C): 1,944 · Conversion (C): 97,615 · +6 more | EDGAR |
| 2020-12-04 | 4 | OrbiMed Israel GP Ltd. — 10% owner OrbiMed Israel BioFund GP Limited Partnership — 10% owner | Sale (S): 103,200 @ $21.60 | EDGAR |
| 2020-11-06 | 4 | Logos Global Management LP — 10% owner | Purchase (P): 5,000 @ $24.03 · Purchase (P): 31,000 @ $24.53 · Purchase (P): 4,000 @ $25.97 · Purchase (P): 15,000 @ $26.48 · Sale (S): 12,942 @ $26.64 · Purchase (P): 12,942 @ $25.88 · +3 more | EDGAR |
| 2020-09-15 | 4 | Kuwahara Jon — See Remarks | Grant/award (A): 2,145.26 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | Gros David-Alexandre C — Chief Executive Officer, Director | Grant/award (A): 18,278.14 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | McBride John S. — Director | Grant/award (A): 1,167.21 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | Katkin Keith — Director | Grant/award (A): 5,907.15 (derivative) @ $0 | EDGAR |
| 2020-09-15 | 4 | LYONS GARY A — Director | Grant/award (A): 1,167.21 (derivative) @ $0 | EDGAR |
Recent 8-K events — Eledon Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-02 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NVUS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs